Print this page    •   Back to Web version of article

Switching Isentress to Once a Day Is Less Effective

February 2011

Although the integrase inhibitor Isentress (raltegravir) is recommended for people going on treatment for the first time, it's the only first line drug that's taken twice, not once, a day. In an effort to simplify the dosing, a study compared taking Isentress twice a day vs. once a day.

Unfortunately, the 48-week results showed that fewer people who took Isentress once a day (83%) had undetectable viral loads below 50 copies compared to those who took it twice a day (89%). The reason for this is likely because the drug is quickly processed out of the body. Although this difference appears slight it was statistically significant, thereby showing once a day does not provide an equal level of HIV suppression that twice a day does, especially in people who started treatment at viral loads over 100,000.




This article was provided by Project Inform. It is a part of the publication Project Inform Perspective. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art61071.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.